RPLP1

Large ribosomal subunit protein P1 · P05386 · RPLP1 on Sugi Atlas →

3,677 patent compounds predicted against RPLP1, 1,927 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPLP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults	nan	COMPLETED
NFC Changes in SLE Patients and Its Correlation With Anti-U1RNPAntibodies and Disease Activity	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Genetics of Rolandic Epilepsy	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome)	nan	COMPLETED
Identification of New FTLD Genes	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPLP1 binder may also engage these)

Protein	Name	Similarity
Q56K14	—	1.000	Q56K14 →
P19944	—	1.000	P19944 →
P47955	—	1.000	P47955 →
O23095	—	1.000	O23095 →
Q8LCW9	—	1.000	Q8LCW9 →
Q9HGV0	—	1.000	Q9HGV0 →
P17476	—	1.000	P17476 →
O01359	—	1.000	O01359 →
P08570	—	1.000	P08570 →
P22684	—	1.000	P22684 →
H2E5X2	—	1.000	H2E5X2 →
P18660	—	1.000	P18660 →
P05318	—	0.999	P05318 →
Q9UU78	—	0.999	Q9UU78 →
P29763	—	0.999	P29763 →
Q49KL9	—	0.998	Q49KL9 →
P52855	—	0.998	P52855 →
P02402	—	0.998	P02402 →
P91913	—	0.997	P91913 →
O46313	—	0.997	O46313 →
P50344	—	0.996	P50344 →
Q8LEQ0	—	0.996	Q8LEQ0 →
P17477	—	0.996	P17477 →
Q06382	—	0.995	Q06382 →
A1XQU7	—	0.994	A1XQU7 →
P27055	—	0.994	P27055 →
P42039	—	0.994	P42039 →
Q96UQ7	—	0.994	Q96UQ7 →
Q9HFQ7	—	0.993	Q9HFQ7 →
P17478	—	0.993	P17478 →